Cargando…
FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer
A 40-year-old female with familial adenomatous polyposis (FAP) had a subtotal colectomy at 16 years of age. At 39 years, she had low anterior resection due to advanced rectal carcinoma. Thereafter, we administrated per os uracil and tegafur for 9 months. Metastatic rectal carcinoma was detected in t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073807/ https://www.ncbi.nlm.nih.gov/pubmed/21487565 http://dx.doi.org/10.1159/000112652 |
_version_ | 1782201648244850688 |
---|---|
author | Mori, Mitsue Kiba, Takayoshi Oikawa, Mika Hokkoku, Kengou Watanabe, Yuri Shintaku, Kimiko Yoshimitsu, Yutaka Sakuma, Hiroshi Ueda, Hiroshi Nakai, Masuo |
author_facet | Mori, Mitsue Kiba, Takayoshi Oikawa, Mika Hokkoku, Kengou Watanabe, Yuri Shintaku, Kimiko Yoshimitsu, Yutaka Sakuma, Hiroshi Ueda, Hiroshi Nakai, Masuo |
author_sort | Mori, Mitsue |
collection | PubMed |
description | A 40-year-old female with familial adenomatous polyposis (FAP) had a subtotal colectomy at 16 years of age. At 39 years, she had low anterior resection due to advanced rectal carcinoma. Thereafter, we administrated per os uracil and tegafur for 9 months. Metastatic rectal carcinoma was detected in the liver (S8) by computed tomography (CT). 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) data did not show any other metastasis. This report presents a first case of a patient undergoing subtotal colectomy administered FOLFIRI (CPT-11 180 mg/m(2) as a 90-minute infusion on day 1; leucovorin 400 mg/m(2) as a 2-hour infusion during CPT-11, immediately followed by 5-FU bolus 400 mg/m(2) and 46-hour continuous infusion of 2,400 mg/m(2) every 2 weeks). This regimen was administered without grade 3 or 4 of any adverse reaction for 6 months, although there was a possibility that this patient with subtotal colectomy may have the cause for severe diarrhea. Further investigations are needed to assess the safety in clinical trials of FOLFIRI regimen for patients with subtotal colectomy. |
format | Text |
id | pubmed-3073807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-30738072011-04-12 FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer Mori, Mitsue Kiba, Takayoshi Oikawa, Mika Hokkoku, Kengou Watanabe, Yuri Shintaku, Kimiko Yoshimitsu, Yutaka Sakuma, Hiroshi Ueda, Hiroshi Nakai, Masuo Case Rep Gastroenterol Published: December 2007 A 40-year-old female with familial adenomatous polyposis (FAP) had a subtotal colectomy at 16 years of age. At 39 years, she had low anterior resection due to advanced rectal carcinoma. Thereafter, we administrated per os uracil and tegafur for 9 months. Metastatic rectal carcinoma was detected in the liver (S8) by computed tomography (CT). 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) data did not show any other metastasis. This report presents a first case of a patient undergoing subtotal colectomy administered FOLFIRI (CPT-11 180 mg/m(2) as a 90-minute infusion on day 1; leucovorin 400 mg/m(2) as a 2-hour infusion during CPT-11, immediately followed by 5-FU bolus 400 mg/m(2) and 46-hour continuous infusion of 2,400 mg/m(2) every 2 weeks). This regimen was administered without grade 3 or 4 of any adverse reaction for 6 months, although there was a possibility that this patient with subtotal colectomy may have the cause for severe diarrhea. Further investigations are needed to assess the safety in clinical trials of FOLFIRI regimen for patients with subtotal colectomy. S. Karger AG 2007-12-31 /pmc/articles/PMC3073807/ /pubmed/21487565 http://dx.doi.org/10.1159/000112652 Text en Copyright © 2007 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published: December 2007 Mori, Mitsue Kiba, Takayoshi Oikawa, Mika Hokkoku, Kengou Watanabe, Yuri Shintaku, Kimiko Yoshimitsu, Yutaka Sakuma, Hiroshi Ueda, Hiroshi Nakai, Masuo FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer |
title | FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer |
title_full | FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer |
title_fullStr | FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer |
title_full_unstemmed | FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer |
title_short | FOLFIRI Is Tolerable after Subtotal Colectomy – A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer |
title_sort | folfiri is tolerable after subtotal colectomy – a patient with familial adenomatous polyposis who developed advanced rectal cancer |
topic | Published: December 2007 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073807/ https://www.ncbi.nlm.nih.gov/pubmed/21487565 http://dx.doi.org/10.1159/000112652 |
work_keys_str_mv | AT morimitsue folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT kibatakayoshi folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT oikawamika folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT hokkokukengou folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT watanabeyuri folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT shintakukimiko folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT yoshimitsuyutaka folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT sakumahiroshi folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT uedahiroshi folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer AT nakaimasuo folfiriistolerableaftersubtotalcolectomyapatientwithfamilialadenomatouspolyposiswhodevelopedadvancedrectalcancer |